Introduction
The p53 gene family has three members, TP53, TP63 and TP73. The tumor suppressor p53 is expressed at low levels in most cells and tissues but accumulates on cellular stress such as DNA damage, oncogene activation and hypoxia, and triggers cell cycle arrest, senescence and/or apoptosis (for a review, see Vousden and Lu (2002) ). Mutations in p53 occur in nearly half of all human tumors (Olivier et al., 2002) . p63 and p73 share structural homology with p53, particularly in their DNA-binding domains, with >60% amino acid identity (Kaghad et al., 1997; Schmale and Bamberger, 1997; Osada et al., 1998; Trink et al., 1998; Yang et al., 1998; Zeng et al., 2001) . All three proteins take part in the regulation of cell cycle progression and apoptosis, and are expressed as several different isoforms because of alternative promoter usage and splicing. The full-length proteins (p53, TAp63 and TAp73) function as transcription factors. p63 and p73 are commonly expressed as so called DN isoforms that lack the N-terminal transactivation (TA) domain. The DN isoforms can block the TA activity of the full-length proteins by forming complexes or by competing for DNA-binding sites (Grob et al., 2001; Stiewe et al., 2002; Chan et al., 2004) . Several studies have also shown that DNp63 can activate transcription through an additional N-terminal TA domain (Ghioni et al., 2002; Helton et al., 2006) .
Mice null for p63 or p73 show severe developmental or neurological and immunological defects, respectively, and die at young age, thus making it difficult to evaluate the effect of p63 and p73 on cancer susceptibility (Mills et al., 1999; Yang et al., 1999 Yang et al., , 2000 Suh et al., 2006) . Although p63 and p73 are rarely mutated in human tumors (Strano et al., 2001 ), inactivation of p63 or p73 can contribute to tumor development in mice, and loss of p63 and p73 can cooperate with p53 in tumor suppression (Flores et al., 2005; Guo et al., 2009) . A recent study demonstrated that TAp63 knockout mice show enhanced genomic instability and premature aging as well as defects in maintaining skin proliferation and differentiation (Su et al., 2009) . Mice with an isoformspecific deletion of TAp73 show a high incidence of spontaneous tumors and increased sensitivity to carcinogens, establishing TAp73 as a bona fide tumor suppressor (Tomasini et al., 2008) . Methylation-induced silencing of the TAp73 promoter has been found in lymphoblastic leukemias and Burkitt lymphomas (Corn et al., 1999; Kawano et al., 1999) . The DNp73 and TAp73 isoforms are co-upregulated in primary rhabdomyosarcomas and tumor-derived cell lines, as compared with normal muscle (Cam et al., 2006) . DNp73 isoforms are expressed at high levels in many different tumor types and are related to poor prognosis (Buhlmann and Putzer, 2008) . Thus, accumulating evidence clearly indicates that both TAp63 and TP73 may have a role in tumor development.
We previously identified PRIMA-1, a low molecular weight compound that triggers apoptosis in human tumor cells through restoration of the transcriptional TA function to both structural and DNA contact mutant p53 (Bykov et al., 2002a, b) . PRIMA-1 MET / APR-246 (2-hydroxymethyl-2-methoxymethyl-aza-bicyclo[2.2.2]octan-3-one) is a methylated form of PRIMA-1 with even higher potency (Bykov et al., 2005b) . We will henceforth refer to it as PRIMA-1 MET . PRIMA-1 MET induces mutant p53-dependent apoptosis via multiple signaling pathways including upregulation of mitochondrial p53 target proteins such as Bax, Puma, and Noxa, activation of caspase-2, and ER stress (Shen et al., 2008; Lambert et al., 2010) . PRIMA-1 has also been shown to trigger mutant p53-mediated transcription-independent apoptosis (Chipuk et al., 2003) . Treatment with PRIMA-1
MET induces nucleolar accumulation of mutant p53 and the PML nuclear body (PML-NB) associated proteins PML, CBP and Hsp70, which probably has a role in PRIMA-1 MET -induced apoptosis (Ro¨kaeus et al., 2007) . Recently, we demonstrated that PRIMA-1 and PRIMA-1 MET are converted to MQ, a Michael acceptor that binds covalently to the p53 core domain in vitro and in vivo and thus triggers mutant p53-dependent apoptosis (Lambert et al., 2009) . Here, we show that PRIMA-1 MET targets mutant forms of p63 and p73. PRIMA-1
MET treatment causes upregulation of p53/p63/p73-target genes and a redistribution of mutant p63 to PML-NBs and nucleoli, and induces mutant p63/p73-dependent apoptosis.
Results
Mutant p63/p73-dependent growth suppression and induction of apoptosis by PRIMA-1
MET
To study whether PRIMA-1 MET could suppress the growth of tumor cells in a mutant p63/p73-dependent manner, we treated H1299 cells stably expressing temperature-sensitive (ts) mutant TAp73a (H1299-tsp73a), TAp73b (H1299-tsp73b) and TAp63g (H1299-tsp63g) and parental H1299 cells with 0-40 mM PRIMA-1 MET for 24 h at 39 1C and examined cell growth using the WST-1 cell proliferation reagent. Treatment of cells expressing ts mutant TAp63g and TAp73b with PRIMA-1 MET at 39 1C resulted in significant growth suppression as compared with H1299 control cells (Figures 1a and b) Figures  1e and f) , whereas the H1299-tsp73a cells were fairly resistant to PRIMA-1 MET -induced apoptosis.
Upregulation of p21 mRNA and protein by PRIMA-1
Western blot analysis verified that the ts p63/p73-mutants were transcriptionally inactive at 39 1C but adopted a transcriptionally active conformation resulting in induction of p21 on temperature shift to 32 1C (Figure 2a ). To test whether PRIMA-1
MET could act at the transcription level as well, we treated H1299, H1299-tsp73a, H1299-tsp73b and H1299-tsp63g cells at 39 1C and studied the effect on p21 mRNA and protein levels by real-time reverse transcriptase-PCR and western blot analysis. We found that PRIMA-1 MET -induced p21 both at the mRNA and protein level in cells expressing ts TAp73b and TAp63g, but not in H1299-tsp73a cells (Figures 2b and c) . Some p21 mRNA induction was also observed in H1299 cells. Moreover, real-time reverse transcriptase-PCR showed a weak induction of Bax mRNA in H1299-tsp73b cells treated with 50 mM PRIMA-1 MET (data not shown).
PRIMA-1 MET targets point mutant p63 and p73 We next generated expression vectors for the mutants TAp63g-R204W, TAp63g-R304W, TAp73a-R193H and TAp73b-R193H that correspond to p53 hot spot mutations at residues 175 and 273. We transiently transfected HCT116 p53
À/À cells with these mutants, treated the transfected cells with PRIMA-1 MET for 24 h and assessed the fraction of annexin V-positive cells by FACS. PRIMA-1 MET caused a significant increase in the number of annexin V-positive cells among the cells expressing mutant p63 or p73 as compared with empty vector control cells (Supplementary Figure 1) .
To further examine the effect of PRIMA-1 MET in the presence or absence of mutant p63, we generated individual clones of Saos-2 cells stably expressing Tetinducible (Tet-On) TAp63g-R204W or TAp63g-R304W. These mutations in the p63 DNA-binding domain are associated with the EEC syndrome (Rinne et al., 2007) . Western blotting revealed a robust increase in p63 protein expression on addition of doxycycline in all cell lines (Figures 3b and c , and data not shown). However, p63 was also expressed at significant levels in the absence of doxycycline in clone TAp63g-R304W-29 (Figure 3b ). p63 expression in the absence of doxycycline in clones TAp63g-R204W-16 and TAp63g-R304W-2 could only be visualized after much longer exposure ( Figure 3c ).
All cell lines were treated with PRIMA-1 MET for 72 h, and cell proliferation was assessed by WST-1 reagent. We observed that PRIMA-1 MET suppressed cell growth in a mutant p63-dependent manner in all TAp63g clones ( Figure 4a ). Moreover, treatment with PRIMA-1 MET increased the fraction of mutant TAp63g-expressing
MET /APR-246 targets mutant p63 and p73 N Rökaeus et al Saos-2 cells with a sub-G1 DNA content ( Figure 4b ) and active caspases (data not shown), indicating cell death by apoptosis. This effect was more pronounced in the presence than in the absence of doxycycline for the TAp63g-R304W-2 and TAp63g-R304W-29 cells, confirming that expression of mutant p63 conferred increased sensitivity to PRIMA-1 MET -induced apoptosis ( Figure 4b , right panel). For the TAp63g-R204W-expressing cells, we observed a significant increase in cells in the G1 phase and a decreased S-phase fraction, indicating that this mutant promotes cell cycle arrest in response to PRIMA-1 MET treatment ( Figure 4c and Supplementary table 1).
PRIMA-1
MET causes redistribution of mutant p63 We previously found that PRIMA-1 MET treatment causes a nucleolar accumulation of mutant p53, along with PML, CBP and Hsp70 (Ro¨kaeus et al., 2007) .
To study whether PRIMA-1 MET affects the subcellular localization of mutant p63, we treated Saos-2-TetTAp63g-R204W, Saos-2-Tet-TAp63g-R304W cells with PRIMA-1 MET and examined the cellular distribution of p63 by immunofluorescence staining. Treatment with PRIMA-1 MET induced a redistribution of both p63 mutants to PML-NBs and nucleoli in up to B40% of the cells. The relocalization was partial, with a fraction of mutant p63 remaining in nucleoplasm after treatment (Supplementary Figure 2 and data not shown). Treatment with PRIMA-Dead, a structural analog of PRIMA-1
MET that is inactive with regard to induction of apoptosis did not induce any changes in mutant p63 distribution (data not shown). Moreover, treatment with cisplatin or the mutant p53-targeting compound MIRA-1 (Bykov et al., 2005a) , did not induce cellular redistribution of mutant p63 to any significant extent in these cells (data not shown). We next examined protein levels of the p63 downstream targets p21, Noxa and keratin 14 after PRIMA-1 MET treatment. Western blot analysis revealed induction of both p21 and Noxa by PRIMA-1 MET in a mutant p63-dependent manner (Figure 6a ). Induction of Noxa protein was confirmed by immunofluoresence staining (Figure 6b) . We also observed a modest but significant induction of keratin 14 protein expression after treatment with PRIMA-1 MET at concentrations that did not induce apoptosis (5 up to 20 mM) ( Figure 6c , left panel; data not shown). Keratin 14 was also induced in Saos-2 cells transiently transfected with a wild-type TAp63g construct (0.5 up to 1 mg) ( Figure 6c , right panel; data not shown). We did not detect any keratin 14 induction after transfection with higher amounts of wild-type TAp63g plasmid (42 mg) that induced cell death (data not shown).
Discussion
The low molecular weight compounds PRIMA-1 and PRIMA-1 MET /APR-246 restore wild-type function to mutant p53 and trigger mutant p53-dependent apoptosis (Bykov et al., 2002b) . As the DNA-binding domains of p53, p63 and p73 share high sequence homology, we hypothesized that PRIMA-1 MET might be active against mutant forms of p63 and p73 as well. Our analysis of ts mutants of p63 and p73 revealed that mutant TAp73b and TAp63g but not TAp73a conferred increased sensitivity to PRIMA-1 MET treatment. Moreover, transient overexpression of mutant TAp73a or TAp73b in HCT116 p53
À/À cells showed that although both mutant TAp73a and TAp73b could enhance apoptosis after PRIMA-1 MET treatment, mutant TAp73b was more potent than mutant TAp73a in this regard. Finally using Saos-2 cells stably expressing Tet-regulated mutant TAp63g-R204W or TAp63g-R304W, we show that PRIMA-1 MET can restore either growth suppression or apoptotic functions to mutant TAp63g. Thus, our analysis demonstrates significant differences among mutant p63 and p73 isoforms with respect to their ability to confer an apoptotic response to PRIMA-1 MET . Activation of ts TAp63g and TAp73a in H1299 cells by temperature shift induced apoptosis, whereas activation of TAp73b resulted in increased cell size and inhibition of cell division (Pochampally et al., 2000) . In contrast, PRIMA-1 MET induced apoptosis in cells expressing ts TAp63g and TAp73b but not in ts TAp73a-expressing cells, suggesting that temperature shift and PRIMA-1 MET treatment act differently with respect to restoring wild-type function to mutant p73. It is conceivable that adducts of the PRIMA-1 MET conversion product MQ could create novel protein-DNA contacts (Lambert et al., 2009 (Lambert et al., , 2010 . This could affect the choice of target genes and thus result in a different biological outcome than reactivation by temperature shift. Moreover, PRIMA-1 MET could also PRIMA-1 MET /APR-246 targets mutant p63 and p73 N Rökaeus et al target other proteins in the cell, which might lead to synergistic effects promoting apoptosis rather than growth arrest.
Structurally, TAp63g and TAp73g most closely resemble full-length p53 (Figure 3) . TAp63g is as potent as p53 in transactivation and apoptosis assays (Yang et al., 1998) . The TAp63a and TAp73a isoforms on the other hand, contain a so called sterile a motif domain and a transactivation inhibitory domain in their C-terminal regions. The C-terminal region may have a regulatory role and modulate the ability of TAp63a and TAp73a to induce gene expression (Ozaki et al., 1999; Ueda et al., 1999) . TAp73b induced a stronger apoptotic response compared with TAp73a when exogenously expressed in tumor cells or untransformed cells (Gonzalez et al., 2005) . The lower transcription and apoptotic activity in response to particular stress signals of the TA a isoforms of both p63 and p73 was attributed to the sterile a motif domain and the TA inhibitory domains, which are absent in the b and g isoforms (Scoumanne et al., 2005) . Thus, these structural differences among the p63 and p73 isoforms could explain the robust growth suppression and apoptosis on PRIMA-1 MET treatment in cells expressing the mutant TAp63g or TAp73b isoform and the much less pronounced effect in cells expressing mutant TAp73a.
We have previously observed that PRIMA-1 and PRIMA-1 MET can induce redistribution of mutant p53 from the nucleoplasm to nucleoli, and that the PML-NB-associated proteins PML, CBP and Hsp70 also accumulate in nucleoli (Ro¨kaeus et al., 2007) . PML is a transcription target of p53 and PML overexpression was shown to recruit p53 into PML-NBs and stabilize p53 (Fogal et al., 2000; de Stanchina et al., 2004) . In accordance with our previous observations for p53, we observed mutant TAp63g relocalization to PMLNBs and nucleoli after PRIMA-1 MET treatment, but not after treatment with the inactive PRIMA-1 structural analog PRIMA-Dead. Whether PML-NBs have a similar role for p63 activation and acetylation as they do for p53 is not known. However, it was observed that p63 could localize to PML-NBs, in which it interacts with PML and that this interaction increases p63 transcriptional activity (Bernassola et al., 2005) .
We extended our studies of the effect of PRIMA-1 MET to naturally occurring p63 mutants that have a causative role in the EEC syndrome. Although mutations in p63 and p73 do not occur frequently in human tumors, mutations in the p63 gene are the major cause of the EEC syndrome in humans (Celli et al., 1999; van Bokhoven et al., 2001 ). This autosomal dominant disorder is characterized by ectodactyly, ectodermal dysplasia and facial clefting. Most of these mutations give rise to amino acid substitutions in the DNAbinding domain of p63. The arginines at codons 204, 227, 279, 280 and 304, are the most frequently mutated residues, accounting for almost 90% of all EEC syndrome cases. Interestingly, these germline p63 mutations correspond exactly to the somatic hot spot p53 mutations in human tumors. We confirmed that PRIMA-1 MET can restore wild-type properties to two different TAp63g mutants that occur in the EEC syndrome. Importantly, the binding of mutant TAp63g-R204W and TAp63g-R304W to a p53/p63 consensus Moreover, PRIMA-1 MET -induced p63 downstream targets related to both apoptosis and differentiation. In the case of TAp63g-R304W, mutant p63-dependent growth suppression was also reflected as mutant p63-dependent induction of cell death as assessed by FACS-PI. TAp63g-R204W expression did not enhance DNA fragmentation in response to PRIMA-1 MET , but in contrast caused cell cycle arrest. Thus, it is clear that these two mutants of TAp63g show different responses to PRIMA-1 MET treatment, but the exact reasons remain to be elucidated. TAp63g-R204W and TAp63g-R304W are presumably different with regard to structural disturbances of the core domain, which might affect the outcome of reactivation by PRIMA-1 MET , in terms of regulation of target genes and induction of specific biological responses. Interestingly, we found that low doses of PRIMA-1 MET induced the differentiation marker and p63 target keratin 14 in TAp63g-R204W Saos-2 cells, although less potently than transfection of the same cells with wild-type TAp63g. Future studies should address whether PRIMA-1 MET can restore the capacity of mutant isoforms of p63 to induce differentiation in a relevant cellular background, that is, human keratinocytes carrying naturally occurring mutant p63 and/or keratinocytes from EEC or ankyloblepharon-ectodermal defects-cleft lip/palate syndrome patients.
In conclusion, we have shown that PRIMA-1 MET can restore wild-type activity to mutant forms of all three p53 family members. Thus, PRIMA-1 MET has a broader activity than for example the compound CP-31398 that was shown to restore DNA-binding activity to mutant p53 but does not affect p63 and p73 (Demma et al., 2004) . Our results indicate that PRIMA-1 MET exerts its effects through a common mechanism for p53, p63 and p73, presumably involving homologous structural domains of all three target proteins. A better understanding of the molecular mechanism behind PRIMA-1 MET -mediated apoptosis is clearly important for further development of PRIMA-1 MET toward efficient anticancer drugs. The effect of PRIMA-1 MET on mutant p63 described here also raises the possibility of pharmacological rescue of mutant p63 in developmental syndromes caused by p63 mutations.
Materials and methods
Cell lines and reagents H1299 is a human p53 null lung adenocarcinoma cell line. H1299 cells stably expressing ts mutants of TAp73a, TAp73b and TAp63g (kindly provided by Dr Jiandong Chen, H Lee Moffitt Cancer Center) have been described (Pochampally et al., 2000) . These cells are referred to as H1299-tsp73a, H1299-tsp73b and H1299-tsp63g, respectively. Cells were maintained in Iscove's modified Dulbecco's medium (supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 40 mg/ml gentamicin) at 39 1C in 5% CO 2 . Human HCT116 (p53
) colon carcinoma cells (kindly provided by Dr Bert Vogelstein, Johns Hopkins Oncology Center) were maintained in McCoy's 5A medium with 10% fetal bovine serum and 2 mM L-glutamine. Saos-2 cells carrying Tet-regulated (Tet-On) mutant TAp63g (see below) were maintained in Iscove's modified Dulbecco's medium supplemented with 10% Tetfree fetal bovine serum, 2 mM L-glutamine and 2.5 mg/ml plasmocin at 37 1C in 5% CO 2 . These cells were maintained under selection with 0.5 mg/ml puromycin and 600 mg/ml geneticin. Doxycycline at 0.1 mg/ml was used for induction of TAp63g.
Antibodies
The following antibodies were used for immunofluorescence staining, flow cytometry and western blotting: mouse monoclonal anti-p63 (4A4; Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse monoclonal anti-p73 (Ab-2/ER-15; Oncogene Research Products, San Diego, CA, USA), mouse monoclonal anti-p21 (Cip1/WAF1; BD Biosciences, Stockholm, Sweden), mouse monoclonal anti-Noxa (OP180/ 114C307; Calbiochem, Darmstadt, Germany), rabbit polyclonal anti-Keratin 14 (AF 64; Covance, San Diego, CA, USA), mouse monoclonal anti-p53 (DO7; kindly provided by Dr Sir David Lane, University of Dundee), mouse monoclonal anti-b-actin (AC-15; Sigma-Aldrich, Stockholm, Sweden) and rabbit polyclonal anti-PML (H-238; Santa Cruz PRIMA-1 MET /APR-246 targets mutant p63 and p73 N Rökaeus et al Generation of cells expressing Tet-regulated human mutant TAp63g TAp63g R204W and R304W mutants were generated by GeneArt, Germany. They were subcloned into the pTRE2pur vector (Clontech, Heidelberg, Germany) between the BamHI and NotI sites. p53 null Saos-2 osteosarcoma cells containing the pUHD172-1neo plasmid were stably transfected with pTRE2pur-TAp63g-R204W, pTRE2pur-TAp63g-R304W or pTRE2pur empty vector using lipofectamine 2000 (Invitrogen AB, Stockholm, Sweden) according to the manufacturer's instructions. Cells were selected with 1 mg/ml Puromycin (Sigma Aldrich, St Louis, MO, USA), single colonies picked and analyzed by immunostaining and western blotting. These cells will be referred to as Saos-2-Tet-TAp63g-R204W, Saos-2-TetTAp63g-R304W and Saos-2-Tet-Ctrl.
WST-1 growth suppression assay Cells were grown in 96-well plates overnight followed by PRIMA-1 MET treatment. Cell viability was assessed after 24, 48 and 72 h using the WST-1 cell proliferation reagent (Roche, Basel, Switzerland) according to the manufacturer's instructions. Data were analyzed by Microcal Origin statistical software (Origin Lab, Northampton, MA, USA).
Flow cytometry
Cells were grown overnight and treated with PRIMA-1 MET the next day. Cell cycle assays: following treatment, all cells were collected, fixed with 70% ethanol, treated with RNase A, and stained with propidium iodide. Caspase activity assays: active caspase-positive cells were assessed using FAM-VAD-FMK substrate (CaspaTag Pan-Caspase in situ assay kit, APT400, Chemicon, Hampshire, UK) according to manufacturer's instructions. Keratine 14 staining: cells were collected by trypsinization and fixed with 50% ethanol overnight. Pelleted cells were incubated with primary and secondary antibody diluted in TgT buffer (0.01% Triton X-100; 20mM Tris, pH 7.4; 150 mM NaCl; 20% fetal bovine serum).
Samples were analyzed on a FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) according to standard procedures. Data were analyzed by WinMDI 2.8, FCS Express 3.0 (De Novo Software, Los Angeles, CA, USA) and Microcal Origin statistical software (Origin Lab, Northampton, MA, USA).
Real-time reverse transcriptase-PCR Cells were plated in six-well plates and treated with PRIMA-1 MET the next day. Following treatment cells were harvested by trypsinization. RNA was isolated using RNeasy mini kit (Qiagen, Stockholm, Sweden) according to the manufacturer's instructions. Complementary DNA was synthesized as described earlier (Zache et al., 2008) . In all, 100 ng of each sample was analyzed in duplicates using TaqMan probes; Hs00560402_m1 (PMAIP1/Noxa), s00355782_m1 (CDKN1A/ p21) and Hs99999905_m1 (glyceraldehyde 3-phosphate dehydrogenase) (Applied Biosystems, Foster City, CA, USA). Reactions were performed using the ABI PRISM 7500 Sequence Detection System (Applied Biosystems). Results were analyzed with the comparative Ct method using glyceraldehyde 3-phosphate dehydrogenase as the endogenous control.
TransAm assay for DNA binding Nuclear lysates were extracted using the Nuclear Extract Kit according to the manufacturer's protocol (Active Motif, Tegernheim, Germany, 40010) and incubated in a 96-well plate coated with immobilized oligonucleotides that contains a p53/p63 consensus-binding site (5 0 -GGACATGCCCGGGCA TGTCC-3 0 ; TransAM kit, Active Motif, 41196). Bound p63 protein was detected by a mouse monoclonal anti-p63 antibody and a secondary horseradish peroxidase-conjugated antibody. The signal was quantified by spectrophotometry (450 nm).
Western blotting Cells were grown overnight followed by PRIMA-1 MET -treatment or temperature shift. Cells were lysed and analyzed by western blotting according to standard procedures. Protein bands were visualized using SuperSignal West Femto Maximum Sensitivity substrate (Pierce, Rockford, IL, USA). Image densitometry was performed using the Image Gauge version 3.12 analysis software (Fuji, Japan).
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